Genetic Technologies : Quarterly Investor Presentation

ersonal use only

Quarterly Investor Presentation

January 21, 2022

Authorised by the Board of Directors of Genetic Technologies Limited

ASX: GTG

NASDAQ: GENE

ersonal use only

Notice: Forward looking statements

The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

ersonal use only

Our Overview

01

02

03

04

05

06

Our Vision & Brand	Our Markets	Our Acquisition	Our Channels &	Our Portfolio &	Our Capabilities
Pillars			Divisions	Innovation
2021 Overview	Expanded to over 40	EasyDNA - Execution a	Pathways, Divisions and	Executing through cutting	Aligning our internal capability
Where are	countries	multi brand strategy	Category Segmentation	edge innovation and 'game	aligned to execution
we now				changing' partnerships

3

ersonal use only

1. Unlocking personalised preventative health

Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.

We're transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment - where each person has the information, they need to manage their health according to their own risk.

Backed by over 20 years of experience, our doctors, scientist and technicians are translating genetic information into multi-tests that uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.

We're empowering physicians to improve health outcomes for people around the world. Tracking disease to its source. Enabling a new era of personalised medicine.

4

1. geneType's pillars reflect its commitment to personalised, preventative health

ersonal use only

Unequalled experience

Scientific team leveraging their extensive research track record in breast and colorectal to expand our medical- grade genetic test portfolio into further cancers and chronic conditions

Relentless innovation

Accelerating the world's transition to personalised, preventative health care by converting genetic data into actionable solutions for consumers and doctors

Leading integrated technology

The sophisticated integration of genomic and clinical risk factors deliver the most complete risk assessments for serious diseases in the world - the foundation of geneType

Setting new standards

Setting clinical, safety and ethical standards to ensure the best health outcomes

genetype's Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals

5